Several studies have shown that higher CSF and serum CHI3L1 levels are correlated with the degree of disability and cognitive impairment in patients with progressive MS (PPMS and SPMS) compared to control patients [5,32,73,84,96,104,105,106]. The gene discussed is CHI3L1; the disease is secondary progressive multiple sclerosis.